Bio-Rad Laboratories BIO Asia Pacific — Net Sales
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Rad Laboratories's asia pacific — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Rad Laboratories's asia pacific — net sales?
- Bio-Rad Laboratories (BIO) reported asia pacific — net sales of $110.4M in Q1 2026.
- How has Bio-Rad Laboratories's asia pacific — net sales changed year-over-year?
- Bio-Rad Laboratories's asia pacific — net sales increased by 6.1% year-over-year, from $104.1M to $110.4M.
- What is the long-term trend for Bio-Rad Laboratories's asia pacific — net sales?
- Over 4 years (2021 to 2025), Bio-Rad Laboratories's asia pacific — net sales has grown at a -7.1% compound annual growth rate (CAGR), from $688.4M to $513.3M.
- What does asia pacific — net sales mean?
- The total revenue earned by the company from customers located in the Asia Pacific region.
- How do you interpret asia pacific — net sales?
- An increase indicates successful market expansion, higher adoption of diagnostic and research technologies, or favorable economic conditions in the region. A decrease may signal increased local competition, regulatory hurdles, or a slowdown in regional healthcare and research spending.
- How does asia pacific — net sales compare across companies?
- Peers in the life sciences and diagnostics sector typically report regional revenue splits to highlight geographic exposure; this metric is comparable to 'Asia-Pacific Revenue' reported by global healthcare equipment and supply companies.